Search PubMed⌕ Search

Biomedical subjects

C R Reinemeyer

Publications and source records attributed to C R Reinemeyer.

At least 19 recordsLinked to original sources
PubMed2006

A multicenter evaluation of the effectiveness of Quest Gel (2% moxidectin) against parasites infecting equids.

Controlled trials with a common protocol were conducted in Idaho, Illinois and Tennessee to evaluate anthelmintic effectiveness of Quest Gel (QG; 2% moxidectin) against lumenal parasites in horses. Candidate horses were required to have naturally acquired nematode infections, as confirmed by presence of strongylid eggs in feces. At each site, 24 equids were blocked on the basis of pretreatment strongyle fecal egg counts (EPG) and randomly assigned to treatments within blocks. Within each block of two animals, one received QG on Day 0 at a dosage of 0.4 mg moxidectin/kg b.w. and one was an untreated control. Body weights measured the day before treatment served as the basis for calculating treatment doses. Horses assigned to treatment with QG received the prescribed dose administered orally with the commercially packaged Sure Dial syringe. Horses were necropsied 12-14 days after treatment, and lumenal parasites and digesta were harvested separately from each of five organs, including the stomach, small intestine, cecum, ventral colon and dorsal colon. Parasites from stomachs and small intestines were identified to genus, species and stage. Micro- (i.e., < 1.5 cm) and macroparasites (i.e., > 1.5 cm) in aliquots from the cecum, ventral colon and dorsal colon were examined in aliquots of approximately 200 parasites until at least 600 parasites had been identified to genus, species and stage or until all parasites in the 5% aliquot were examined, whichever occurred first. Data were combined across sites and analyzed by mixed model analysis of variance to assess the fixed effect of treatment and random effects of site and block within site. Because QG does not contain a cestocide, efficacy of QG against tapeworms was not significant (P > 0.05). Based on geometric means, however, efficacy of QG was greater than 90% (P < 0.05) against 38 species and developmental stages of cyathostomes, strongyles, bots, larval pinworms and ascarids encountered in at least 6 of 36 control horses in the combined data set. None of the horses treated with moxidectin exhibited evidence of adverse effects. Study results demonstrate QG, administered to horses with naturally acquired endoparasite infections at a dosage of 0.4 mg moxidectin/kg b.w., was highly effective against a broad range of equine parasitic infections.

Analysis of Variance↗
PubMed2005

Evaluation of the efficacy of emodepside+praziquantel topical solution against cestode (Dipylidium caninum, Taenia taeniaeformis, and Echinococcus multilocularis) infections in cats.

Emodepside+praziquantel topical solution was developed to provide broad-spectrum anthelmintic activity against gastrointestinal parasites in cats. Eight controlled studies were conducted to evaluate the efficacy of a topical solution of emodepside (3 mg/kg) and praziquantel (12 mg/kg) (Profender, BayerAG, Leverkusen, Germany) against feline infections with three species of cestodes. Studies featured naturally acquired infections of Dipylidium caninum or Taenia taeniaeformis, or experimental infections with Echinococcus multilocularis that were placebo-controlled, randomized and blinded. Cats were euthanatized and necropsied between 2 and 11 days after treatment, depending on the target parasite. The efficacy of emodepside+praziquantel topical solution was 100% against D. caninum and T. taeniaeformis, and 98.5- 100% against E. multilocularis. No significant systemic or local adverse reactions to treatment were noted in cats that received the combination. Topical treatment of cats with emodepside+praziquantel topical solution was safe and highly effective against cestode infections.

Administration, Topical↗
PubMed2005

Evaluation of the efficacy of emodepside plus praziquantel topical solution against ascarid infections (Toxocara cati or Toxascaris leonina) in cats.

Eleven controlled studies were conducted in the United States and Europe to evaluate the efficacy of a topical solution of emodepside (3 mg/kg)+praziquantel (12 mg/kg) (Profender, Bayer AG, Leverkusen, Germany) against infection with various stages of the ascarid nematodes Toxocara cati and Toxascaris leonina. Infections were induced by administration of larvated ascarid eggs, and stage-specific efficacy was evaluated by treating cats at scheduled intervals post-inoculation. All studies featured random allocation to treatment groups, placebo-treated control animals and assessment of outcome measures by masked personnel. The product (emodepside+praziquantel topical solution) was 100% effective against mature adults and immature adult T. cati. In addition, it was 96.8% effective against third stage larvae and at least 99.4% effective against fourth stage larvae of T. cati, respectively. Efficacy against mature, immature adult and L4 stages of T. leonina exceeded 93.4%, but regulatory "adequacy of infection" criteria were not met in some studies. No adverse reactions to treatment were noted in cats treated with the emodepside+praziquantel topical solution.

Administration, Topical↗
PubMed2002

Dose confirmation studies of moxidectin 1% non-aqueous injectable and moxidectin 0.5% pour-on formulations against experimentally induced infections of larval and adult stage Oesophagostomum radiatum and Trichuris discolor in cattle.

Separate controlled trials were conducted to evaluate the efficacy of two formulations of moxidectin (1% non-aqueous injectable solution and 0.5% pour-on (Cydectin) against larval or adult stages of Oesophagostomum radiatum and Trichuris discolor infecting cattle. Fifty-three strongylate-free dairy breed steer calves were obtained from commercial sources. After a brief acclimation period, calves were randomly divided into two pools to evaluate the efficacy of the moxidectin formulations against targeted larval (n = 27 calves) or adult (n = 26 calves) parasites. Calves in the larvacidal trial were inoculated on Day -16 relative to treatment with approximately 1000 embryonated Trichuris spp. eggs and approximately 640 infective Oesophagostomum spp. larvae. Calves were allocated by lottery to one of three treatment groups (n = 8 per group), which included: Group 1--moxidectin 0.5% pour-on (0.5 mg/kg body weight (BW)) applied topically; Group 2--moxidectin 1% non-aqueous injectable (0.2 mg/kg BW) administered subcutaneously; Group 3--untreated controls. Treatments were administered on Day 0 and calves were housed by group with no contact among animals of different treatments. Three sentinel calves were necropsied on Day 0 of the larvacidal trial to assess viability of larval inocula. On Days 14, 15 and 16 after treatment, calves were euthanatized (two or three from each group per day) and samples of gut contents were collected for determination of total worm counts. On Day -63 relative to treatment, calves in the adulticidal efficacy trial were inoculated with approximately 1000 embryonated Trichuris eggs and then on Day -35 with approximately 2500 infective Oesophagostomum spp. larvae. Fecal samples were collected on Day -7 and the 24 calves with the highest egg counts were assigned by lottery to the following three treatment groups (n = 8 per group): Group 4--moxidectin 0.5% pour-on; Group 5--moxidectin 1% injectable; Group 6--untreated controls. Details of experimental treatments, calf housing and necropsy scheduling were similar to the larvacidal trial. In both the larvacidal and adulticidal trials, inocula contained a variety of parasites in addition to the targeted species. Based on geometric means, both moxidectin 0.5% pour-on and moxidectin 1% non-aqueous injectable significantly reduced (P < 0.05) numbers of Oesophagostomum spp. and Trichuris spp. with anthelmintic efficacies of >99% when used against adult or larval stages of infection. In addition, both formulations of moxidectin demonstrated >95% efficacy (P < 0.05) against larval stages of Strongyloides papillosus. The pour-on formulation had >97% adulticidal and larvacidal efficacy against Cooperia spp. females, while the injectable product was effective against female Cooperia spp. larvae and Cooperia oncophora adult males.

Administration, Topical↗
PubMed2002

Comparison of endoscopic, necropsy and histology scoring of equine gastric ulcers.

Equine gastric ulcer syndrome (EGUS) represents a major health problem in performance horses. Much debate exists regarding endoscopic gastric ulcer scoring systems and their ability accurately to predict severity or depth of gastric ulcers. The purpose of this study was to evaluate the ability of an endoscopist to count gastric ulcers and predict gastric ulcer severity or depth using 2 endoscopic scoring systems and compare them to the same gastric ulcers see on necropsy and histopathology. Endoscopic examination of the stomach was performed under general anaesthesia on 23 mixed breed yearling horses, after feed was withheld for 24 h. Gastric ulcers were scored using 2 systems, number/severity-scoring (N/S) and practitioner simplified (PS) systems. After endoscopy, the horses were subjected to euthanasia and the stomach mucosa examined blindly and scored again at necropsy using above scoring systems. Representative gastric ulcers were then placed in 10% formalin and processed routinely for histopathology. The gastric ulcers were scored using a histopathology system (HSS) based on ulcer depth. Number scores in the N/S scoring system and PS on endoscopic and necropsy examinations were compared using Friedman 2 way analysis of variance. Where significant differences between variables were found a post hoc analysis was conducted using a Tukey's Studentised range (HSD) test. Severity scores using the N/S (ENGS) and PS scores recorded for the stomach via endoscopy and scores from HSS were evaluated for significant association using a Mantel-Haenszel Chi-square and Pearson moment correlation coefficient analysis. Significance was P < 0.05. All horses had gastric ulcers in the nonglandular mucosa via endoscopic examination and at necropsy examination. Mean nonglandular ulcer number (ENGN) score was significantly (P = 0.0024) lower on endoscopic examination compared to the score at necropsy (NNGN); whereas PS scores were not significantly different on endoscopy when compared to necropsy examination. A significant but weak association was found between ENGS and HSS (3.89, P = 0.048; r = 0.453, P = 0.045) and no correlation was found between PS and HSS (1.2, P = 0.272; r = 0.117; P = 0.622). Only 1/23 horses had glandular ulcers observed via endoscopic examination whereas, 6/23 horses had glandular ulcers at necropsy and on histopathology. The prevalence of EGUS is high in stalled yearling horses. The endoscopist may underestimate the number of gastric ulcers and may not be able accurately to predict the severity or depth of those ulcers present in the nonglandular equine stomach. Furthermore, the endoscopist may miss glandular gastric ulcers.

Animals↗
PubMed2000

Efficacy of moxidectin equine oral gel against endoscopically-confirmed Gasterophilus nasalis and Gasterophilus intestinalis (Diptera: Oestridae) infections in horses.

A 3 m, video gastroscope was used to screen 47 horses suspected of being naturally infected with equine bot larvae. 17 of 47 (36.2%) candidate horses harbored Gasterophilus nasalis larvae in the proximal duodenum and 46 of 47 (97.9%) had G. intestinalis larvae in the stomach. All horses infected with G. nasalis had concurrent infections with G. intestinalis. 14 horses with dual infections were allocated randomly to two treatment groups. Seven horses in Group 1 received 2% moxidectin oral gel once at a dosage of 0.4 mg/kg bodyweight (BW), and seven horses in Group 2 were untreated controls. 14 days after treatment, all horses were necropsied and the stomach and proximal duodenum harvested from each. Bot larvae were recovered, identified to species and instar, and counted. At the label dosage, moxidectin oral gel was 100 and 97.6% effective (P < 0.05) against third-instar G. nasalis and G. intestinalis, respectively. In addition to demonstrating the boticidal efficacy of moxidectin, this trial illustrated that gastroscopy/duodenoscopy is a feasible method for confirming infections with different species of bot larvae in the horse.

Administration, Oral↗
PubMed1999

Current concerns about control programs in temperate climates.

Efforts to control cyathostome nematodes in temperate climates have not been uniformly successful, as evidenced by contemporary reports of clinical disease and widespread anthelmintic failure. Indeed, effective control is confounded by numerous factors, including ignorance of local transmission patterns, confusing or conflicting control recommendations, and use of ineffective anthelmintics or regimens. Most of these problems are universal rather than being climatically unique, and it is important to recognize that they are mere symptoms of larger and more comprehensive problems. The most basic problem in managing cyathostomes is inadequate knowledge of biological factors that influence control recommendations. These include population dynamics, arrested development, host resistance, and regional bionomics. Another hindrance is the absence of objective criteria to define effective control. Target fecal egg counts are arbitrary and subjective, and parameters to measure the subclinical impact of cyathostome infection in well-managed horses have not been identified. The final general challenge to effective parasite control is motivation and education of equine practitioners and horse owners, who currently receive much of their parasite control information in the form of biased advertising. Ultimately, more effective equine parasite control will result from collaborative efforts of basic research, clinical application, and improved information transfer.

Animals↗
PubMed1997

Results of a survey to assess knowledge and expectations of veterinarians and their clients regarding heartworm preventives and vaccinations in dogs.

OBJECTIVE: To determine the knowledge and expectations of veterinarians and clients regarding heartworm preventives and annual vaccinations for dogs. DESIGN: Practitioner and client survey. SAMPLE POPULATION: 435 veterinarians and 1,805 clients. PROCEDURE: A survey was mailed to veterinarians requesting information from them and their dog-owning clients on expectations and knowledge regarding heartworm preventives and annual vaccinations. Responses of veterinarians were compared with those of clients, and both were compared with label indications. RESULTS: Expectations of veterinarians and clients regarding heartworm preventives were similar and usually were consistent with regulatory interpretation of label terms. Of clients purchasing heartworm preventives, 38% did not know that the medication was effective against intestinal nematodes. Veterinarians and clients would be unsatisfied with a product that reduced, but did not eliminate, all intestinal nematodes. Most clients knew that annual vaccinations included distemper virus, parvovirus, and rabies virus, but about half of them did not know that other antigens were in the vaccines. CLINICAL IMPLICATIONS: Effects of heartworm preventives and diseases for which dogs are annually vaccinated should be explained fully to clients.

Animals↗
PubMed1995

Comparison of the efficacies of three heartworm preventives against experimentally induced infections with Ancylostoma caninum and Toxocara canis in pups.

Forty 11- to 12-week-old helminth-naive Beagles were categorized by sex and weight and randomly assigned to 4 treatment groups (group 1, ivermectin/pyrantel pamoate; group 2, milbemycin oxime; group 3, untreated control; group 4, diethylcarbamazine/oxibendazole). Each pup was inoculated PO with approximately 100 infective Ancylostoma caninum larvae and 100 larvated Toxocara canis eggs on day 0, and repeatedly at 7-day intervals thereafter until day 56. Administration of anthelmintics also began on day 0, and subsequent treatments were administered according to label recommendations at 30-day intervals (groups 1 and 2) or daily (group 4) for a period of 90 consecutive days. Body weight and A caninum and T canis fecal egg counts were measured at weekly intervals, and clinical observations of health status were conducted twice daily. Pups were euthanatized on day 90, and total gastrointestinal worm burdens were determined. Compared with mean A caninum egg counts of group-3 control pups, egg counts in group-1 pups were significantly (P < or = 0.0001) lower on every sampling days 35, 42, 49, 63, 70, 77, and 84, and were consistently the highest of all treated groups, and egg counts of group-4 pups were significantly (P < or = 0.0001) lower on every sampling date from day 14 to day 90, and were consistently the lowest of all treated groups. Compared with mean A caninum egg counts of group-3 pups, egg counts in group-1 and group-2 pups were lower by 97.8 and 90.8%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Age Factors↗
PubMed1995

Effects of housing and colostrum feeding on serum immunoglobulins, growth, and fecal scores of Jersey calves.

Ninety-six Jersey calves were used to evaluate the effects of housing and method of colostrum feeding on serum Ig concentrations, incidence and severity of scours, intake, and BW changes from birth to 35 d of age. Calves were separated from the dam and fed 2 L of colostrum in nipple-bottles or allowed to nurse the dam for 3 d. Calves were housed in individual hutches or wooden pens in a barn. Intake of colostrum by calves allowed to nurse the dam was not controlled. Serum IgG and IgM concentrations at 24 h of age were greater for calves that nursed the dam. Scours were less severe when calves were housed in hutches, but number of days scouring was unaffected by treatment. Calves fed colostrum in nipple-bottles and housed in the barn consumed more starter than did other calves from 3 to 5 wk of age. The BW were greater for calves allowed to nurse the dam and housed in hutches. Feed efficiency over the 35-d study was improved when calves nursed the dam. Optimal transfer of passive immunity and housing in hutches appeared to maximize health and growth in this study.

Animal Nutritional Physiological Phenomena↗
PubMed1994

Effects of housing and colostrum feeding on the prevalence of selected infectious organisms in feces of Jersey calves.

Neonatal Jersey calves (n = 96) were used to evaluate effects of housing (individual hutches or wooden pens in a barn) and colostrum feeding (calves were separated from the dam and fed 2 L of colostrum in nipple-bottles or allowed to nurse the dam for 3 d) on the prevalence of selected organisms in feces. Prevalence of Cryptosporidium and Eimeria were reduced, and prevalence of rotavirus tended to be reduced, when calves were housed in hutches. Prevalence of coronavirus was unaffected by treatment. Weekly prevalence of Giardia was increased when calves were left to nurse the dam for 3 d. Mean prevalence of Cryptosporidia (wk 1 to 4), Eimeria (wk 4 to 5), Giardia, rotavirus, and coronavirus (wk 1 to 5) were 34.7, 20.6, 27.1, 15.8, and 4.9%, respectively. Escherichia coli (K99 positive) were observed in 3 of 174 samples cultured. Methods of housing and colostrum feeding affected acquisition of enteropathogens in this study.

Animals↗
PubMed1992

Effects of lasalocid on coccidial infection and growth in young dairy calves.

Effects of lasalocid on coccidial infection and on calf growth were examined in 16 Holstein bull calves. Calves were assigned randomly to a 2 x 2 factorial arrangement of starter ration containing 0 or 40 mg of lasalocid/kg of starter, beginning when calves were 3 days old (SE = 0.046), and single oral inoculation with 0 or 30,000 sporulated oocysts (Eimeria bovis) at 28 days. Pelleted calf starter was fed ad libitum from day 1; milk replacer was fed at a rate of 3.6 kg/d until day 28. Mean daily gain, dry-matter intake, and body weight were increased in calves fed lasalocid and decreased in those inoculated with coccidia. Addition of lasalocid to the feed improved gains by 8% in uninoculated calves and by 50% in inoculated calves. Fecal oocyst numbers were reduced when lasalocid was fed to inoculated calves. Feces were more abnormal in calves inoculated with coccidia. Respiration rates, rectal temperatures, PCV, and serum sodium and potassium concentrations were unaffected by treatment. On the basis of findings in this study, lasalocid minimized effects of coccidial challenge inoculation and increased growth of calves.

Animal Feed↗
PubMed1992

A survey of ovine parasite control practices in Tennessee.

A sample of 126 sheep producers in Tennessee was randomly selected from the members of a statewide organization of sheep producers. Data about the participants' farms, sheep, parasite control practices and sources of information regarding ovine parasite control were obtained by a telephone survey. The response rate was 99%. The typical respondent kept 20 lambs, 20 ewes and 2 rams on three pastures totalling 20 acres. In order of decreasing frequency, anthelmintics were given according to a regular schedule, to coincide with breeding management procedures, or to treat clinical signs of parasitism. Proportions of producers deworming the various classes of sheep zero, one, two, three, four or more than four times annually were as follows: lambs--3, 28, 40, 16, 9 and 8%, respectively; ewes--3, 8, 20, 16, 34 and 22%, respectively; rams--1, 9, 19, 15, 38 and 19%, respectively. The majority of respondents planned to deworm lambs (89%) and ewes (82%) the same number of times in the following year. Of the producers who dewormed sheep two or more times during 1989, 39-49% (ranges include different proportions for lambs, ewes and rams) used the same anthelmintic exclusively, and 51-61% used two or more drug classes. Of the owners using a single anthelmintic exclusively, most (39-66%) used ivermectin, followed by levamisole (19-33%) and benzimidazoles (13-24%). One hundred and three of 124 (83%) producers intended to use the same anthelmintics in the future. Sixty-four of 124 (52%) producers had discontinued using at least one ovine anthelmintic. The most common reasons for discontinuance were dissatisfaction with the clinical response after treatment and inconvenience of administration. Sheep-oriented publications, other sheep producers and veterinarians were considered the most important sources of information about deworming programs and choice of anthelmintics.

Animals↗
PubMed1990

A survey of equine parasite control practices in Tennessee.

A weighted, random sample of 130 horse owners in Tennessee was selected from subscribers to an equine newsletter published by the Agricultural Extension Service. Data about the participants' farms, horses, parasite control practices, and sources of information regarding equine parasite control were obtained through a telephone survey. The response rate was 98%. The typical respondent kept 4 horses on 2 pastures totaling 15 acres, and did not rotate pastures as a parasite control measure. The majority (83%) of horse owners indicated that they administered anthelmintics according to a regular schedule; 9% delayed deworming until the onset of weight loss. Proportions of owners deworming the various classes of horses at least 1, 2, 3, or 4 times annually were as follows: foals (0 to 6 months) 100, 60, 15, and 0%, respectively; weanlings (6 to 12 months) 100, 91, 32, and 0%, respectively; yearlings (1 to 2 years) 100, 100, 86, and 51%, respectively; and adults (greater than 2 years) 100, 94, 56, and 24%, respectively. Median treatments of yearlings and adults were evenly spaced at 6-, 4-, or 3-month intervals when the owners dewormed 2, 3, or 4 times annually, respectively. Mean intervals between treatments of foals and weanlings were less regular. Of the horse owners who dewormed 2 or more times annually, most (53 to 80%) used the same product exclusively for all treatments. In all age classes of horses, ivermectin paste (46 to 63%) was the most common product used, followed by tube deworming (23 to 38%) and use of benzimidazoles (4 to 16%).(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1990

Evaluation of the efficacy and safety of two formulations of pyrantel pamoate in cats.

The efficacy of paste and granule formulations of pyrantel pamoate against concurrent infections of Toxocara cati and Ancylostoma tubaeforme in cats was examined in a controlled trial. Three groups of 8 cats received either no medication (controls) or pyrantel pamoate in paste or granule formulations at a dosage of 20 mg/kg of body weight. After administration of the paste formulation, fecal egg counts of A tubaeforme and T cati were decreased by 98.6 and 96.4%, respectively, and 100% of hookworms and 93.5% of ascarids were removed from the intestine. After administration of the granule formulation, fecal egg counts of A tubaeforme and T cati were decreased by 99.4 and 78.2%, respectively, and 100% of adult hookworms and 88.9% of ascarids were removed. All reductions of egg counts and worm numbers were significant (P less than 0.01). The clinical safety of pyrantel pamoate was evaluated in 4- to 6-week-old kittens. Three groups of 10 kittens received either no medication (controls) or pyrantel pamoate in paste or granule formulations at the rate of 100 mg/kg for 3 consecutive days. Adverse effects were not observed in young kittens following administration of the high dose of pyrantel pamoate.

Administration, Oral↗